Arcus Biosciences (RCUS) Other Non-Current Liabilities (2017 - 2026)

Arcus Biosciences' Other Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $119.0 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 28.31% year-over-year to $119.0 million; the TTM figure through Mar 2026 stood at $119.0 million (down 28.31% YoY), while the FY2025 annual figure was $135.0 million, down 14.01% from the prior year.
• Other Non-Current Liabilities was $119.0 million for Q1 2026 at Arcus Biosciences, down from $135.0 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $166.0 million in Q1 2025 to a low of $13.9 million in Q1 2022.
• Historically, Other Non-Current Liabilities has averaged $121.3 million across 5 years, with a median of $140.0 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Other Non-Current Liabilities jumped 945.12% in 2023, then slipped 28.31% in 2026.
• A 5-year view of Other Non-Current Liabilities shows it stood at $140.0 million in 2022, then grew by 1.43% to $142.0 million in 2023, then rose by 10.56% to $157.0 million in 2024, then fell by 14.01% to $135.0 million in 2025, then declined by 11.85% to $119.0 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $119.0 million (Q1 2026), $135.0 million (Q4 2025), and $152.0 million (Q3 2025), per Business Quant data.